Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
Provided By GlobeNewswire
Last update: Oct 25, 2024
Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea®) in Healthy Subjects
Read more at globenewswire.comNASDAQ:FBIO (6/16/2025, 8:00:02 PM)
1.84
-0.01 (-0.54%)
6.74
-0.04 (-0.59%)
Find more stocks in the Stock Screener
